Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAIYUN: As-needed PT027 versus PT007 in symptomatic adult asthma in China
CTR20241676Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Jul 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in asthma comparing PT027 as needed with PT007 as needed (2 arms). Primary endpoint: Time to first severe asthma exacerbation. Started Jul 2024; status: active.
02
Drugs
salbutamol + budesonidealbuterol sulfate
03
Conditions
asthma
Beyond the preview
Go deeper on CTR20241676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241676.